Hims discloses SEC probe as its legal woes mount
Hims & Hers said that it is under investigation by the Securities and Exchange Commission, adding another legal challenge for the telehealth company.
The SEC requested that it preserve records related to its compounded GLP-1 treatments, Hims disclosed in a regulatory filing on Monday. The news came after the company reported earnings results and gave soft full-year guidance.
Shares extended losses to down more than 8% in postmarket trading after the 10-K, which detailed this probe, was released.
Hims is already facing a patent infringement lawsuit from Novo Nordisk and a potential probe from the Department of Justice. Both arose after Hims released (and then discontinued) a copy of Novo’s Wegovy pill.
From the company’s 10-K filing:
“In February 2026, the Company received a letter from the staff of the Securities and Exchange Commission, Division of Enforcement, notifying the Company that it had opened an investigation and requesting that the Company preserve certain documents and information concerning the Company’s public statements and disclosures regarding compounded semaglutide and related business relationships (the ‘SEC Investigation’). The Company is cooperating with the SEC Investigation but is unable to predict when or how this matter will be concluded. Therefore, the financial impact of the SEC Investigation cannot be predicted at this time.”
Hims is already facing a patent infringement lawsuit from Novo Nordisk and a potential probe from the Department of Justice. Both arose after Hims released (and then discontinued) a copy of Novo’s Wegovy pill.
From the company’s 10-K filing:
“In February 2026, the Company received a letter from the staff of the Securities and Exchange Commission, Division of Enforcement, notifying the Company that it had opened an investigation and requesting that the Company preserve certain documents and information concerning the Company’s public statements and disclosures regarding compounded semaglutide and related business relationships (the ‘SEC Investigation’). The Company is cooperating with the SEC Investigation but is unable to predict when or how this matter will be concluded. Therefore, the financial impact of the SEC Investigation cannot be predicted at this time.”
